Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regent Pacific GroupRPGLF 14 3-Year EBITDA Growth Rate is 40.70% as of Dec. 2025, which is 251% above its 10-year median of 11.60. GuruFocus rates RPGLF with a GF Score™ of 14/100. The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Regent Pacific Group ranks better than 85.36% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 40.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Regent Pacific Group was 52.80% per year. The lowest was -63.70% per year. And the median was 11.60% per year.
Regent Pacific Group (OTCPK:RPGLF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Regent Pacific Group 3-Year EBITDA Growth Rate Related Terms
RPGLF vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Regent Pacific Group's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regent Pacific Group 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Regent Pacific Group's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Regent Pacific Group's 3-Year EBITDA Growth Rate falls into.
Regent Pacific Group 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 40.70% mean?
Regent Pacific Group (RPGLF) has a 3-Year EBITDA Growth Rate of 40.70% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regent Pacific Group and its competitors. This is 251% above median its historical median of 11.60. According to the industry distribution chart, Regent Pacific Group ranks #119 out of 813 companies in the Drug Manufacturers industry, placing it in the top 14.6%.
Is Regent Pacific Group's 3-Year EBITDA Growth Rate too high?
Regent Pacific Group's current 3-Year EBITDA Growth Rate of 40.70% is 251% above median its 10-year median of 11.60. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.80. Regent Pacific Group's value of 40.70% is 362.5% above this industry median. Based on the distribution chart, Regent Pacific Group ranks #119 out of 813 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Regent Pacific Group has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Regent Pacific Group's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Regent Pacific Group ranks #119 out of 813 companies for 3-Year EBITDA Growth Rate. This places Regent Pacific Group in the top 15% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.80. Regent Pacific Group's value of 40.70% is 362.5% above this benchmark. While the company's 10-year median is 11.60 vs. the industry median of 8.80, Regent Pacific Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.80, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regent Pacific Group's current 3-Year EBITDA Growth Rate of 40.70% is 362.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Regent Pacific Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regent Pacific Group's current 3-Year EBITDA Growth Rate is 40.70%, which is 251% above median its own 10-year median of 11.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regent Pacific Group stock overvalued right now?
Regent Pacific Group (RPGLF) has a current 3-Year EBITDA Growth Rate of 40.70%. The current 3-Year EBITDA Growth Rate is 40.70%, which is 251% above median its 10-year median of 11.60 and 362.5% above the Drug Manufacturers industry median of 8.80. Regent Pacific Group's overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Regent Pacific Group (RPGLF), the current 3-Year EBITDA Growth Rate is 40.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regent Pacific Group Ltd is an investment holding company that runs through two segments: Biopharma and Corporate Investment. Its Biopharma segment is engaged in the research, development, manufacturing, marketing, and sales of pharmaceutical products, and it also develops artificial intelligence (AI) systems for the field of biological aging clocks. The Corporate Investment segment is engaged in the investment in listed and unlisted corporate entities. The majority of its revenue comes from the Biopharma segment. Geographically, the Europe; U.S.; and Asia Pacific. It derives maximum revenue from Europe.
14GF Score
Get the complete analysis for RPGLF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RPGLF has been successfully added to your 
